Market Pulse
Market Pulse

Affidea's fifth Swiss healthcare buy in 19 months

Affidea announced on 24 September 2026 the acquisition of Zentrum für Integrative Onkologie (ZIO AG), founded in Glarus in 2015 by oncologists around medical director Boris Hübenthal. ZIO runs six sites in German-speaking Switzerland with about 100 employees, more than 20 of them oncology and haematology specialists.

Patiswiss AG of Gunzgen announced on 22 September 2026 that it will take over the nut business of Hans Nobs & Cie AG of Münchenbuchsee on 1 January 2027, including brand, customers, recipes and production equipment but excluding the real estate. Production moves to Gunzgen.

Of 15 register filings published 21 to 25 September that the old method counted as deals, nine state that one owner already held both companies. Between 1 June and 13 September the share was 72% (666 of 927), and only 16 filings (1.7%) issued new shares to the owners of the absorbed company.

5Press-Reported Deals-17% WoW
627Distress Events+6% WoW
1Startup FundingCHF 4.6M converted
13Succession Signals+62% WoW
997New Registrations+5% WoW
2378Board Changes+1% WoW

Affidea makes its fifth Swiss purchase in 19 months. On 24 September it bought ZIO, the integrative oncology centres founded in Glarus in 2015: six sites between Glarus and Zurich, about 100 staff and 26,000 consultations last year. Before ZIO came a pathology laboratory group, the Uroviva urology network, the LabPoint laboratories and Berner Urologen. The Belgian investment company GBL has owned Affidea since 2022.

The order of the purchases is the strategy. Laboratories make the diagnosis, urologists treat the prostate, and oncologists run the chemotherapy. For the founder of a multi-site specialist practice around Zurich, there is now a buyer with a plan and a record, and that is the benchmark any other first offer will be measured against.

In family exits, the business is sold and the property stays. Patiswiss takes over the Nobs nut business from January: brand, customers, recipes and machines, but not the Münchenbuchsee property. Granovit is buying the feed maker utro Fikovit and closing its Emmenbrücke mill, and the seller joins Granovit's board. In both deals the buyer paid for what earns money and left the real estate with the family.

Distress: one estate with technology a buyer could use. Of the week's 372 bankruptcies, it is Libattion, the Opfikon maker of battery storage from used EV cells, which had raised EUR 14 million. Separately, m3 REAL ESTATE, part of Abdallah Chatila's Geneva group, entered a definitive moratorium to March 2027.

What the register calls a merger

From 1 June to 13 September, 927 register filings were classified as mergers or asset transfers between companies. We read the notices. In 666 of them, 72%, the text says that one owner already held every share of both companies: a parent absorbing a subsidiary, or two sister companies combined. Another 12 were demergers. In only 16 filings, 1.7%, did the absorbing company issue new shares to the owners of the company it took over, the one wording that proves two different owners were involved. The remaining filings are asset transfers or notices that do not say who owns what.

The reason is structural. In Switzerland a company is sold by selling its shares, and the register publishes nothing when an AG's shares change hands. What it publishes is the aftermath: board members leaving and arriving, then, often a year later, the absorption into the buyer. KNAPP bought ARIKI Solutions in August 2025 and absorbed it only this month. Anyone counting register mergers is counting group tidying. From W38 our deal count excludes filings that state common ownership, and the real deal signals are the board changes that come months before the merger.

The Signals

Unlock the signals — free

Pre-deal signals scored before the press, federal procurement prints, the complete deal tape, the forward court calendar and buyable estates. Free, every Friday.

Free weekly newsletter. Unsubscribe anytime.

Based on 5,819 SOGC/SHAB publications processed this week. M&A data sourced from Swiss commercial registry filings (0 SOGC), press-reported transactions via web intelligence (5 EXA), and startup funding from Startupticker, Tech.eu, and company disclosures (1 round). Company distress scoring based on proprietary multi-signal model across 113,000 Swiss companies. Register deal counts exclude merger and asset-transfer filings whose notice states that one owner held every share of both companies, and demergers; the method changed with 2026-W38. Two register filings survive that rule but are left off the tape because they are group reorganisations the notices do not label as such: Helvetia's Swiss life company transferring CHF 295 million of assets to Baloise Asset Management, and Medical Vision absorbing its subsidiaries Multimed and MedX. Press deals rejected on review: VINCI Energies/CDD Automation, whose record combined a W37 event with an unrelated 2022 source. The forward radar carries one name: the scored list was dominated by large-group subsidiaries, and Sincopharm, a prior radar name, moves to Updates.

ValIndex reads every SHAB filing the day it publishes, checks each merger notice for common ownership, and tracks succession, distress and ownership signals across Swiss companies. Request access →